TMO vs IDXX vs QGEN Stock Comparison

Thermo Fisher Scientific, Idexx Laboratories and Qiagen Prices as of Nov 13, 2026 Peers: Industry group
QGEN Qiagen N.V.
$49.90 +9.6% 1M +6.2% 1Y
Market cap
$10.82B
P/E
28.1x
Revenue (TTM)
$2.12B
Div. yield
–
Life Sciences Tools Healthcare
2 wins

Head to Head

11 decided of 12

Idexx Laboratories leads on 6 of the 12 questions below (Idexx Laboratories 6, Thermo Fisher Scientific 3, Qiagen 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionTMOIDXXQGENLeader
Larger companyMarket capitalisation $255.60B $55.34B $10.82B TMO
Cheaper on earningsLower P/E, profitable companies only 36.1x 46.8x 28.1x QGEN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 27.0x 44.6x 21.2x QGEN
Faster revenue growthRevenue growth, trailing twelve months +8.3% +11.9% +2.2% IDXX
More profitableNet margin, trailing twelve months 14.9% 25.4% 18.2% IDXX
Better return on capitalReturn on invested capital 8.0% 45.4% 7.4% IDXX
Less leveragedLower net debt / EBITDA 3.1x 0.4x 1.2x IDXX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +20.7% +0.4% +6.2% TMO
Better 5-year returnAnnualised price return, 5 years +2.0%/yr +2.3%/yr -3.6%/yr IDXX
Less volatileAnnualised volatility, 1 year 30.7% 36.2% 35.2% TMO
Higher overall scoreMean of the five percentile scores vs peers 60/100 76/100 69/100 IDXX

Percentile Scorecard

TMOIDXXQGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisTMOIDXXQGEN
Valuation 62 #94 of 243 74 #175 of 660 74 #63 of 243
Growth 41 #136 of 228 70 #184 of 619 25 #171 of 228
Profitability 82 #40 of 222 98 #12 of 595 93 #16 of 222
Financial Health 31 #172 of 248 46 #371 of 683 60 #100 of 248
Shareholder Returns 82 #29 of 158 94 #30 of 459 94 #11 of 158
Overall 60 76 69
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • IDXX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • QGEN ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodTMOIDXXQGENSPY
1 month +4.0%+33.1%+9.6% -2.0%
3 months +19.1%+27.8%+16.2% -2.8%
6 months +59.7%+33.2%+51.3% +2.0%
Year to date +20.8%+4.1%+5.4% +10.6%
1 year +20.7%+0.4%+6.2% +12.2%
3 years +52.5%+55.0%+13.0% +68.1%
3 years, per year +15.1%+15.7%+4.2% +18.9%
5 years +10.2%+12.1%-16.9% +61.4%
5 years, per year +2.0%+2.3%-3.6% +10.1%
10 years +362.9%+545.1%+56.5% +248.5%
10 years, per year +16.6%+20.5%+4.6% +13.3%

Risk

MeasureTMOIDXXQGENSPY
Volatility, 1Y 30.7%36.2%35.2% 13.6%
Downside volatility, 1Y 29.2%32.6%29.7% 13.9%
Beta vs S&P 500, 1Y 0.710.840.38 1.00
Return / volatility, 1Y 0.670.010.18 0.90
Max drawdown, 5Y -41.5%-50.9%-48.2% -25.4%
From 52-week high -3.0%-8.1%-10.3% -3.2%
52-week high $721.63$766.68$55.66 $779.14
52-week low $438.34$504.70$32.63 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleTMOIDXXQGEN
P/E now vs peer median 36.6xmedian 26.5x 47.0xmedian 17.0x 28.2xmedian 26.5x
P/S now vs peer median 5.5xmedian 2.7x 11.9xmedian 8.4x 5.1xmedian 2.7x
EV/EBITDA now vs peer median 25.5xmedian 18.4x 33.7xmedian 14.6x 17.7xmedian 18.4x
P/FCF now vs peer median 34.2xmedian 25.4x 42.6xmedian 19.0x 11.2xmedian 25.4x
P/B now vs peer median 4.7xmedian 2.5x 29.7xmedian 2.0x 3.1xmedian 2.5x
PEG now vs peer median 4.84median 0.98 3.10median 0.43 11.74median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsTMOIDXXQGEN
Revenue $47.35B $4.66B $2.12B
Gross profit $19.45B $2.92B $1.33B
Operating income $8.47B $1.51B $448.74M
Net income $7.09B $1.18B $384.93M
Free cash flow $7.60B $1.30B $964.47M
R&D $1.40B $266.87M $199.87M
EPS (diluted) $19.06 $14.96 $1.76
Cash & equivalents $5.46B $197.54M $805.13M
Total debt $41.37B $848.88M $1.64B
Shares (diluted) 371.00M 79.05M 218.88M
Enterprise value $232.12B $54.56B $7.45B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricTMOIDXXQGEN
P/E 36.6x 47.0x 28.2x
P/FCF 34.2x 42.6x 11.2x
P/Operating cash flow 27.8x 39.1x 17.0x
P/S 5.5x 11.9x 5.1x
P/B 4.7x 29.7x 3.1x
P/Tangible book 7.1x 31.7x 3.4x
EV/EBITDA 25.5x 33.7x 17.7x
EV/EBIT 34.8x 37.3x 25.9x
EV/Revenue 6.2x 12.0x 5.5x
EV/FCF 38.8x 43.1x 12.1x
EV/Operating cash flow 31.6x 39.6x 18.3x
PEG (3Y EPS CAGR) 4.84 3.10 11.74

Growth

14 metrics
MetricTMOIDXXQGEN
Revenue growth (1Y) 8.3% 11.9% 2.2%
Revenue CAGR (3Y) 2.9% 9.1% 2.7%
Gross profit growth (1Y) 7.8% 13.7% 1.7%
Gross profit CAGR (3Y) 4.0% 10.8% 2.5%
Operating income growth (1Y) 12.8% 15.3% -7.6%
Operating income CAGR (3Y) 7.2% 11.8% 3.6%
Net income growth (1Y) 7.9% 15.1% -2.8%
Net income CAGR (3Y) 6.2% 12.8% 5.0%
EPS growth (1Y) 9.7% 17.4% -7.3%
EPS CAGR (3Y) 7.6% 15.1% 2.4%
Operating cash flow growth (1Y) 21.9% 30.4% -3.4%
Operating cash flow CAGR (3Y) 4.5% 19.6% 13.7%
Free cash flow growth (1Y) 24.3% 35.3% 1.1%
Free cash flow CAGR (3Y) 5.1% 24.2% 13.5%

Profitability

14 metrics
MetricTMOIDXXQGEN
Gross margin 41.1% 62.7% 62.8%
EBITDA margin 24.4% 35.7% 31.0%
Operating margin 17.9% 32.3% 21.2%
Pretax margin 16.7% 31.7% 21.7%
Net margin 14.9% 25.4% 18.2%
FCF margin 16.0% 28.0% 45.6%
Operating cash flow margin 19.7% 30.4% 30.0%
Return on equity 13.2% 67.9% 11.3%
Return on assets 6.2% 33.1% 6.5%
Return on invested capital 8.0% 45.4% 7.4%
Return on capital employed 8.5% 65.2% 8.5%
Asset turnover 0.4x 1.3x 0.4x
Cash conversion (OCF / net income) 1.3x 1.2x 1.6x
Stock comp / revenue 0.7% 1.4% 2.0%

Financial Health

11 metrics
MetricTMOIDXXQGEN
Debt / assets 36.2% 22.9% 27.6%
Debt / equity 0.8x 0.5x 0.5x
Net debt / EBITDA 3.1x 0.4x 1.2x
Debt / FCF 5.4x 0.7x 1.7x
Liabilities / assets 52.1% 49.6% 41.5%
Equity / assets 47.9% 50.4% 58.5%
Interest coverage 12.0x 43.5x 10.8x
Current ratio 1.8x 1.2x 2.6x
Quick ratio 1.2x 0.7x 1.9x
Cash ratio 0.4x 0.2x 1.3x
Altman Z-score 4.18 23.56 4.14

Shareholder Returns

7 metrics
MetricTMOIDXXQGEN
Dividend yield 0.3% – 5.3%
Net buyback yield 1.6% 1.7% 0.6%
Shareholder yield 1.8% 1.7% 5.9%
Payout ratio (earnings) 9.5% – –
Payout ratio (FCF) 8.9% – –
Dividend growth (1Y) 8.0% – –
Dividend CAGR (3Y) 10.1% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusTMOIDXXQGEN
Forward P/E 27.0xFY2026 44.6xFY2026 21.2xFY2026
EPS, next fiscal year $25.92FY2026 $15.78FY2026 $2.35FY2026
EPS growth, next FY +13.3%FY2026 +20.6%FY2026 -1.3%FY2026
EPS growth, the year after +2.2% +12.3% +17.9%
Revenue, next fiscal year $50.12BFY2026 $5.03BFY2026 $2.25BFY2026
Revenue growth, next FY +12.5%FY2026 +17.0%FY2026 +7.8%FY2026
Revenue growth, the year after -2.7% +0.4% -2.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersTMOIDXXQGEN
Held by institutions 90.2% 93.6% 67.3%
Institutions holding 2,627 1,292 338
Change in shares held, QoQ +0.8% +4.1% +16.5%
Institutions buying 1,145 590 216
Institutions selling 1,145 496 86
Buyers to sellers 1.00 1.19 2.51

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

TMOIDXXQGEN
TMO 1.00 0.29 0.44
IDXX 0.29 1.00 0.19
QGEN 0.44 0.19 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, TMO, IDXX and QGEN?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Thermo Fisher Scientific (TMO) $255.60B, Idexx Laboratories (IDXX) $55.34B, Qiagen (QGEN) $10.82B.

Which stock is cheaper, TMO, IDXX and QGEN?

Qiagen (QGEN) trades on the lowest price-to-earnings ratio (Thermo Fisher Scientific (TMO) 36.1x, Idexx Laboratories (IDXX) 46.8x, Qiagen (QGEN) 28.1x). On next year's consensus earnings, Qiagen (QGEN) is cheapest (Thermo Fisher Scientific (TMO) 27.0x, Idexx Laboratories (IDXX) 44.6x, Qiagen (QGEN) 21.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Idexx Laboratories (IDXX) grew revenue fastest over the trailing twelve months: Thermo Fisher Scientific (TMO) +8.3%, Idexx Laboratories (IDXX) +11.9%, Qiagen (QGEN) +2.2%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Thermo Fisher Scientific (TMO) 14.9%, Idexx Laboratories (IDXX) 25.4%, Qiagen (QGEN) 18.2%). On return on invested capital, Idexx Laboratories (IDXX) leads (Thermo Fisher Scientific (TMO) 8.0%, Idexx Laboratories (IDXX) 45.4%, Qiagen (QGEN) 7.4%).

Which stock has performed better?

Over the past year Thermo Fisher Scientific (TMO) returned the most: Thermo Fisher Scientific (TMO) +20.7%, Idexx Laboratories (IDXX) +0.4%, Qiagen (QGEN) +6.2%. Over five years, Idexx Laboratories (IDXX) compounded fastest (Thermo Fisher Scientific (TMO) +2.0%/yr, Idexx Laboratories (IDXX) +2.3%/yr, Qiagen (QGEN) -3.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Thermo Fisher Scientific (TMO) 0.00%, Idexx Laboratories (IDXX) 0.00%, Qiagen (QGEN) 0.00%. Idexx Laboratories (IDXX) and Qiagen (QGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Thermo Fisher Scientific (TMO) 30.7%, Idexx Laboratories (IDXX) 36.2%, Qiagen (QGEN) 35.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, TMO, IDXX and QGEN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Idexx Laboratories (IDXX) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.